PMID- 38364961
OWN - NLM
STAT- MEDLINE
DCOM- 20240326
LR  - 20240328
IS  - 1872-7980 (Electronic)
IS  - 0304-3835 (Linking)
VI  - 587
DP  - 2024 Apr 10
TI  - Interplay between B7-H3 and HLA class I in the clinical course of pancreatic 
      ductal adenocarcinoma.
PG  - 216713
LID - S0304-3835(24)00106-X [pii]
LID - 10.1016/j.canlet.2024.216713 [doi]
AB  - Human leukocyte antigen (HLA) class I defects are associated with cancer 
      progression. However, their prognostic significance is controversial and may be 
      modulated by immune checkpoints. Here, we investigated whether the checkpoint 
      B7-H3 modulates the relationship between HLA class I and pancreatic ductal 
      adenocarcinoma (PDAC) prognosis. PDAC tumors were analyzed for the expression of 
      B7-H3, HLA class I, HLA class II molecules, and for the presence of 
      tumor-infiltrating immune cells. We observed defective HLA class I and HLA class 
      II expressions in 75% and 59% of PDAC samples, respectively. HLA class I and 
      B7-H3 expression were positively related at mRNA and protein level, potentially 
      because of shared regulation by RELA, a sub-unit of NF-kB. High B7-H3 expression 
      and low CD8(+) T cell density were indicators of poor survival, while HLA class I 
      was not. Defective HLA class I expression was associated with unfavorable 
      survival only in patients with low B7-H3 expression. Favorable survival was 
      observed only when HLA class I expression was high and B7-H3 expression low. Our 
      results provide the rationale for targeting B7-H3 in patients with PDAC tumors 
      displaying high HLA class I levels.
CI  - Copyright (c) 2024 Elsevier B.V. All rights reserved.
FAU - Cattaneo, Giulia
AU  - Cattaneo G
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, United States. Electronic address: https://twitter.com/GCattaneoPhD.
FAU - Ventin, Marco
AU  - Ventin M
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, United States.
FAU - Arya, Shahrzad
AU  - Arya S
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, United States.
FAU - Kontos, Filippos
AU  - Kontos F
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, United States.
FAU - Michelakos, Theodoros
AU  - Michelakos T
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, United States.
FAU - Sekigami, Yurie
AU  - Sekigami Y
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, United States.
FAU - Cai, Lei
AU  - Cai L
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, United States.
FAU - Villani, Vincenzo
AU  - Villani V
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, United States.
FAU - Sabbatino, Francesco
AU  - Sabbatino F
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, United States.
FAU - Chen, Francine
AU  - Chen F
AD  - MacroGenics Inc., Rockville, MD, United States.
FAU - Sadagopan, Ananthan
AU  - Sadagopan A
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, United States.
FAU - Deshpande, Vikram
AU  - Deshpande V
AD  - Department of Pathology, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, United States.
FAU - Moore, Paul A
AU  - Moore PA
AD  - MacroGenics Inc., Rockville, MD, United States.
FAU - Ting, David T
AU  - Ting DT
AD  - MassGeneral Cancer Center, Massachusetts General Hospital, Harvard Medical 
      School, Boston, MA, United States.
FAU - Bardeesy, Nabeel
AU  - Bardeesy N
AD  - MassGeneral Cancer Center, Massachusetts General Hospital, Harvard Medical 
      School, Boston, MA, United States.
FAU - Wang, Xinhui
AU  - Wang X
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, United States.
FAU - Ferrone, Soldano
AU  - Ferrone S
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, United States.
FAU - Ferrone, Cristina R
AU  - Ferrone CR
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, United States; Department of Surgery, Cedars-Sinai Medical Center, 
      Los Angeles, CA, United States. Electronic address: cristina.ferrone@cshs.org.
LA  - eng
PT  - Journal Article
DEP - 20240214
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (B7 Antigens)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (CD276 protein, human)
SB  - IM
MH  - Humans
MH  - B7 Antigens/genetics/metabolism
MH  - B7-H1 Antigen/genetics/metabolism
MH  - *Carcinoma, Pancreatic Ductal/pathology
MH  - Disease Progression
MH  - Histocompatibility Antigens Class I
MH  - Lymphocytes, Tumor-Infiltrating
MH  - *Pancreatic Neoplasms/metabolism
MH  - Prognosis
OTO - NOTNLM
OT  - B7-H3
OT  - HLA class I
OT  - NF-kB
OT  - PDAC
OT  - Tumor microenvironment
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/02/17 10:42
MHDA- 2024/03/26 06:45
CRDT- 2024/02/16 19:14
PHST- 2023/10/17 00:00 [received]
PHST- 2024/01/16 00:00 [revised]
PHST- 2024/02/05 00:00 [accepted]
PHST- 2024/03/26 06:45 [medline]
PHST- 2024/02/17 10:42 [pubmed]
PHST- 2024/02/16 19:14 [entrez]
AID - S0304-3835(24)00106-X [pii]
AID - 10.1016/j.canlet.2024.216713 [doi]
PST - ppublish
SO  - Cancer Lett. 2024 Apr 10;587:216713. doi: 10.1016/j.canlet.2024.216713. Epub 2024 
      Feb 14.